A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Phase 1 Recruiting
398 enrolled
A Study of PHST001 in Advanced Solid Tumors
Phase 1 Recruiting
272 enrolled
SUPRAME
Phase 3 Recruiting
360 enrolled
TroFuse-031
Phase 3 Recruiting
590 enrolled
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Phase 1 Recruiting
330 enrolled
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
340 enrolled
INTerpath-009
Phase 3 Recruiting
680 enrolled
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Phase 3 Recruiting
300 enrolled
TroFuse-011
Phase 3 Recruiting
1,000 enrolled
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
Phase 3 Recruiting
508 enrolled
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
Phase 3 Recruiting
384 enrolled
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Phase 3 Recruiting
574 enrolled
TroFuse-019
Phase 3 Recruiting
780 enrolled
TroFuse-033
Phase 3 Recruiting
1,123 enrolled
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3 Recruiting
2,400 enrolled
FRAmework-01
Phase 3 Recruiting
1,080 enrolled
TroFuse-036
Phase 3 Recruiting
1,023 enrolled
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Phase 3 Recruiting
1,000 enrolled
MAESTRA 2
Phase 3 Recruiting
466 enrolled
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Phase 2/3 Recruiting
1,260 enrolled
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
660 enrolled
CheckMate-1533
Phase 2 Recruiting
76 enrolled
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Phase 3 Recruiting
720 enrolled
LuCa-MERIT-1
Phase 1 Recruiting
320 enrolled
Study of INCB123667 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
604 enrolled
MRD
Phase 1/2 Recruiting
30 enrolled
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Phase 1 Recruiting
500 enrolled
OrigAMI-4
Phase 1/2 Recruiting
287 enrolled
eVOLVE-01
Phase 2 Recruiting
180 enrolled
OVATION-3
Phase 3 Recruiting
500 enrolled
ASPEN-09-03
Phase 2 Recruiting
120 enrolled
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Phase 3 Recruiting
700 enrolled
INTerpath-13
Phase 2 Recruiting
180 enrolled
DE-01
Phase 3 Recruiting
600 enrolled
MUIR
Phase 1 Recruiting
172 enrolled
MountainTAP-29
Phase 2/3 Recruiting
590 enrolled
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
113 enrolled
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Phase 3 Recruiting
398 enrolled
RAMP 301
Phase 3 Recruiting
270 enrolled
MK-2870-010
Phase 3 Recruiting
1,200 enrolled
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Phase 3 Recruiting
851 enrolled
MK-3475-06D
Phase 1/2 Recruiting
210 enrolled
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Phase 2/3 Recruiting
500 enrolled
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Phase 3 Recruiting
625 enrolled
Fern-EC-01
Phase 3 Recruiting
480 enrolled
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
880 enrolled
MK-3475-01E
Phase 2 Recruiting
60 enrolled
ALTAIR
Phase 1/2 Recruiting
152 enrolled
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
260 enrolled
MK-5909-003
Phase 1/2 Recruiting
280 enrolled